Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (29)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Weiss, K.
Right arrow Articles by Guay, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weiss, K.
Right arrow Articles by Guay, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 363-365
© 2000 The British Society for Antimicrobial Chemotherapy

Brief reports

Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia

Karl Weissa,*, Christiane Restieria, Emidio De Carolisb, Michel Laverdièrea and Hélène Guaya

a Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada H1T 2M4 and b Pfizer Pharmaceuticals (Canada), Kirkland, Quebec, Canada

Stenotrophomonas maltophilia is an important emerging pathogen causing a variety of infections in severely ill patients. This microorganism is inherently resistant to many antibiotics, and only a few therapeutic options are available. The principal aim of this study was to assess the in vitro activity of new quinolones against this pathogen. Three hundred and twenty-six single clinical isolates were tested in this study. The MIC90 was 16 mg/L for ciprofloxacin, 8 mg/L for levofloxacin and gatifloxacin, 4 mg/L for trovafloxacin, moxifloxacin and sparfloxacin and 2 mg/L for clinafloxacin. At a 2 mg/L concentration, a Cmax lung:MIC ratio of >=10 can be reached for 95%, 84.3%, 83.1% and 81.5% of isolates, respectively, for clinafloxacin, trovafloxacin, moxifloxacin and sparfloxacin (P < 0.001 compared with levofloxacin and ciprofloxacin). In spite of the rare but serious adverse events associated with the new-generation quinolones, these agents may become very useful in the treatment of certain severe or life-threatening infectious conditions due to S. maltophilia, notably lower respiratory tract infections.

* Corresponding author. Tel: +1-514-252-3817; Fax: +1-514-252-3898; E-mail: weisscan{at}aol.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
B. B. Ba, H. Feghali, C. Arpin, M.-C. Saux, and C. Quentin
Activities of Ciprofloxacin and Moxifloxacin against Stenotrophomonas maltophilia and Emergence of Resistant Mutants in an In Vitro Pharmacokinetic-Pharmacodynamic Model
Antimicrob. Agents Chemother., March 1, 2004; 48(3): 946 - 953.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. A. Dawis, H. D. Isenberg, K. A. France, and S. G. Jenkins
In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms
J. Antimicrob. Chemother., May 1, 2003; 51(5): 1203 - 1211.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. J. Giamarellos-Bourboulis, L. Karnesis, I. Galani, and H. Giamarellou
In Vitro Killing Effect of Moxifloxacin on Clinical Isolates of Stenotrophomonas maltophilia Resistant to Trimethoprim-Sulfamethoxazole
Antimicrob. Agents Chemother., December 1, 2002; 46(12): 3997 - 3999.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
C. Betriu, A. Sanchez, M. L. Palau, M. Gomez, and J. J. Picazo
Antibiotic resistance surveillance of Stenotrophomonas maltophilia, 1993-1999
J. Antimicrob. Chemother., July 1, 2001; 48(1): 152 - 154.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Valdezate, A. Vindel, E. Loza, F. Baquero, and R. Cantón
Antimicrobial Susceptibilities of Unique Stenotrophomonas maltophilia Clinical Strains
Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1581 - 1584.
[Abstract] [Full Text]

Home page
 J Antimicrob ChemotherHome page
J. L. M. Bellido, F. J. S. Hernandez, M. N. G. Zufiaurre, and J. A. Garcia-Rodriguez
In vitro activity of newer fluoroquinolones against Stenotrophomonas maltophilia
J. Antimicrob. Chemother., August 1, 2000; 46(2): 334 - 335.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.